The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
FDA approval of CC-486 for the treatment of adults with AML in first remission
On September 1, 2020, the U.S. Food and Drug Administration (FDA) approved the use of CC-486, oral azacitidine, for the maintenance of adult patients with acute myeloid leukemia (AML) in first remission after intensive induction chemotherapy, who are not able to complete intensive curative therapy. This includes patients in complete remission with incomplete hematological recovery.1
The approval was based on the results of the phase III QUAZAR AML-001 trial (previously reported on the AML Hub), which showed a clinically meaningful improvement in overall survival for patients > 55 years of age, treated with CC-486 plus best supportive care, compared to placebo (24.7 vs 14.8 months, respectively; p = 0.0009). 1
The convenient oral administration of this drug once daily makes it more appealing in this current climate, however, there are warnings that CC-486 should not be substituted for intravenous or subcutaneous azacitidine due to significant differences in pharmacokinetic properties.1
The FDA approval could see treatment with CC-486 become a standard component of AML therapy for adults in first complete remission who cannot proceed to intensive curative therapy.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content